SB505124
目录号 : GC13769Inhibitor of receptors ALK4, ALK5, and ALK7
Cas No.:694433-59-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
SB505124 is a selective and small molecule inhibitor of transforming growth Factor- β type 1 receptors ALK4, ALK5 and ALK7 with the IC50 values of 129±11nM and 47±5nM for ALK4 and ALK5, respectively. [1].
SB505124 has been reported as a potent inhibitor of the in vitro kinase activity of ALK4, ALK5 and ALK7 for its substrate Smad3. In addition, SB505124 has been revealed to be a reversible ATP competitive inhibitor. Moreover, SB505124 has shown no toxicity to renal epithelial A498 cells at concentrations up to 100μM for 48 h. Furthermore, SB505124 has been demonstrated to restrain the TGF-β-induced phosphorylation of Smad2 in three cell lines (HepG2 human hepatoma cells, C2C12 mouse myoblasts and Mv1Lu mink lung cells) in a concentration-dependent manner [1].
References:
[1] DaCosta Byfield S1, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2004 Mar;65(3):744-52.
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.9815 mL | 14.9076 mL | 29.8151 mL |
5 mM | 0.5963 mL | 2.9815 mL | 5.963 mL |
10 mM | 0.2982 mL | 1.4908 mL | 2.9815 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。